ARCHIVES

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

NCAB Approves Addition Of Two New Organ Systems

February 14, 1986

IL-2 Trials Proliferate; Biotherapeutics Sees NCI Proposal As Vindication Of Its Policies

May 8, 1987

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

August 26, 2005

Fisher, NSABP Executive Committee, File Injunction Seeking Herberman’s Removal

August 12, 1994

NCI, IARC Sponsors Workshop On EBV

February 14, 1975

NCI, FDA Courting Drug Sponsors To Add Clinical Trials To PDQ Database

October 11, 1996